Multiple Myeloma

Fewer patients opt to skip therapy for their multiple myeloma (MM) despite progressive disease than previously thought, a new study suggests.

The individual first received their multiple myeloma (MM) diagnosis in 2019.

Bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapies are both associated with an increased risk of infection for patients with multiple myeloma (MM), explained Hans Lee, MD, of The University of Texas MD Anderson Cancer Center.

Authors defined any patient 50 years or younger as a “young” patient.

The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM).

Symptoms initially pointed to toxic alcohol ingestion.

Improving culturally responsive care and practicing cultural humility can help health care providers deliver equitable care for all patients living with multiple myeloma (MM).

There are several reasons patients with multiple myeloma may experience the electrolyte abnormality.

Researchers noted that despite the promising findings, more novel treatments are needed to overcome the disease’s resistance.

The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.

The 68-year-old patient had multiple myeloma and breast cancer.

Authors concluded more research is needed to understand both patient level and structural barriers to inequitable access to multiple myeloma (MM) care in Canada.

Researchers assessed overall survival outcomes in patients in France.

Higher enablement was associated with being more comfortable to reconsult about persistent or worsening symptoms.

Ixazomib was first approved in the United States in 2015 for relapsed/refractory multiple myeloma.

Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.

A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.

Adding motixafortide to standard stem cell mobilization therapy for autologous hematopoietic stem cell transplantation (ASCT) significantly improved collection success rates vs standard therapy plus a placebo in a phase 3 trial of patients with multiple myeloma.

The review aimed to characterize the impacts of clinical response, delayed disease progression, and lines of therapy on health-related quality of life (HRQOL) for patients with multiple myeloma.

A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.

The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.

Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.

A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.

There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found.